James Runo, MD
Pulmonary Disease · Madison, WINPI 1649231564
Payments from drug & device makers
What this record shows
This record is dominated by education: $8 of the $8 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, United Therapeutics Corporation. That places this record below the midpoint for pulmonary disease clinicians in WI, where the typical reported total is $548.
Across 3 payments — averaging $2.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$8
Across 190 payments — averaging $2126.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$289K
- United Therapeutics Corporation$64K
- Actelion Pharmaceuticals, Ltd$26K
- Merck$26K
What the payments were for
- Education$8100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 3 | $8 |
How this compares
$8 in reported general payments places this provider in the 10th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 320 | $4,075,371 |
| Tyvaso DpiTreprostinil | 61 | $1,485,216 |
| AdempasRiociguat | 74 | $1,013,842 |
| UptraviSelexipag | 36 | $961,312 |
| OfevNintedanib Esylate | 68 | $867,765 |
| Ambrisentan | 177 | $527,068 |
| WinrevairSotatercept-Csrk | 33 | $462,028 |
| Bosentan | 28 | $121,572 |
| Pirfenidone | 38 | $110,123 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 96 | $62,321 |
| Sildenafil Citrate | 372 | $32,878 |
| Tadalafil | 53 | $24,698 |
| Advair HfaFluticasone Propion/Salmeterol | 58 | $24,289 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $20,986 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $18,036 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Madison
- Nizar JarjourMadison$35K
- Andrew BraunMadison$33K
- John FergusonMadison$32K
- Stephen HallidayMadison$12K
- Taeha KimMadison$10K
- Mounir FertikhMadison$8K
- Ibrahim Al-SanouriMadison$7K
- Arwa Al-BedourMadison$7K
- Amy JaegerMadison$5K
- Jonathan KurmanMilwaukee$803K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.